February 2013

New Onset of Keratoacanthomas After Vismodegib Treatment for Locally Advanced Basal Cell Carcinomas: A Report of 2 Cases

Author Affiliations

Author Affiliations: Department of Dermatology, Stanford University School of Medicine, Redwood City, California (Drs Aasi, Tang, Wysong, Oro, and Chang and Mr Liu); Division of Ophthalmic Plastic, Reconstructive, and Orbital Surgery, California Pacific Medical Center, Oakland (Dr Silkiss); and Children's Hospital Oakland, Research Institute Oakland, California (Dr Epstein).

JAMA Dermatol. 2013;149(2):242-243. doi:10.1001/jamadermatol.2013.1798

While keratoacanthomas (KAs) and squamous cell carcinomas (SCCs) have been reported in response to a number of systemic drugs such as vemurafenib, sorafenib, or voriconazole,13 their association with Smoothened inhibitors has not been previously noted. Herein, we report 2 cases of new KAs developing within 2 months of starting vismodegib therapy in individuals with no history of KAs or SCCs.

First Page Preview View Large
First page PDF preview
First page PDF preview